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Background: Small studies have found hemoconcentration associated with improved outcomes in hospitalized heart failure (HHF) patients (pts). 
We investigated the patient characteristics and outcomes associated with in-hospital changes in hematocrit in a large cohort of HHF pts with 
ejection fraction (EF) ≤40%.
methods: In 1,684 pts assigned to the placebo arm of the EVEREST trial with available data, in-hospital hematocrit change was calculated as the 
difference between baseline and discharge or day-7 hematocrit (whichever occurred first).
results: Hemoconcentration correlated with in-hospital increases in serum creatinine and urea nitrogen levels and in-hospital decreases in 
glomerular filtration rate and body weight. Over median follow-up of 9.9 months, every 5% increase of in-hospital hematocrit change was associated 
with a decreased risk of all-cause death (Hazard Ratio [HR] = 0.79, 95% Confidence Interval [CI]0.68-0.90) and the composite of cardiovascular 
mortality or heart failure (HF) hospitalization (HR = 0.87, 95% CI 0.78-0.97).
conclusion: In this large cohort of HHF pts with reduced EF, hemoconcentration was associated with decreased mortality and HF hospitalization 
despite an increased risk of worsening renal function.
Table - Baseline Characteristics and Outcomes by In-Hospital Hematocrit Change Quartilea 
Quartile 1
N=467
Quartile 2
N=375
Quartile 3
N=398
Quartile 4
N=444
p-value
In-hospital hematocrit change range (%) -17%, -2% -1%, 0% 1%, 2% 3%, 16% --
Baseline hematocrit (%) 44 ±6 42 ±5 42 ±6 41 ±5 <0.01
Demographics
Age (years) 66 ±12 66 ±12 64 ±12 65 ±12 0.07
Male 349 (75) 287 (77) 306 (77) 338 (76) 0.89
Ischemic heart failure etiology 316 (69) 240 (65) 263 (67) 287 (66) 0.66
New York Heart Association class IV 196 (42) 133 (36) 150 (38) 190 (43) 0.10
Baseline Laboratory Values, Co-morbidities and Medications
Systolic BP (mmHg) 121 ±19 120 ±19 120 ±19 122 ±20 0.30
Heart rate (beats/min) 80 ±17 77 ±14 81 ±15 81 ±16 <0.01
Body weight (kg) 83 ±19 83 ±17 85 ±19 84 ±18 0.08
Ejection fraction (%) 28 ± 8 28 ±8 27 ±8 28 ±8 0.08
B-type natriuretic peptide (pg/mL) 732 (284-1484) 713 (322-1609) 623 (260-1505) 766 (357-1411) 0.58
Serum creatinine (mg/dL) 1.3 (1.1-1.7) 1.3 (1.0-1.5) 1.2 (1.0-1.5) 1.2(1.0-1.5) <0.01
Serum urea nitrogen (mg/dL) 28 (20-40) 26 (19-34) 25 (20-31) 24 (18-33) <0.01
Serum sodium (mEq/L) 140 (137-142) 140 (137-143) 140 (138-143) 140 (137-142) 0.49
Hypertension 344 (74) 257 (69) 274 (69) 311 (70) 0.32
Hyperlipidemia 216 (47) 174 (47) 185 (47) 185 (42) 0.45
Coronary artery disease 335 (72) 264 (70) 285 (72) 305 (69) 0.75
Previous myocardial infarction 242 (52) 192 (51) 210 (53) 228 (52) 0.97
Diabetes mellitus 165 (35) 155 (41) 137 (34) 159 (36) 0.18
Chronic kidney disease 135 (29) 90 (24) 88 (22) 113 (26) 0.13
B-Blockers 324 (70) 261 (70) 281 (71) 315 (71) 0.93
ACEI/ ARB 394 (85) 307 (82) 347 (87) 385 (87) 0.10
Mineralocorticoid Receptor Antagonist 239 (51) 201 (54) 242 (61) 270 (61) <0.01
Digoxin 221 (47) 174 (46) 217 (55) 224 (51) 0.08
In-hospital Changes
Worsening serum creatinine b 59 (13) 39 (11) 45 (12) 89 (20) <0.01
Worsening blood urea nitrogen c 139 (31) 111 (30) 113 (29) 181 (41) <0.01
Worsening glomerular filtration rate d 50 (11) 36 (10) 31 (8) 79 (18) <0.01
Change in body weight (kg) -0.03 -0.03 -0.03 -0.05 <0.01
Outcomes 
All-Cause mortality 139 (30) 97 (26) 86 (22) 89 (20) <0.01
CV mortality 109 (23) 73 (20) 65 (16) 68 (15) <0.01
Sudden cardiac death 35 (8) 23 (6) 21 (5) 28 (6) 0.61
HF hospitalization 135 (29) 102 (27) 103 (26) 111 (25) 0.57
CV hospitalization 178 (38) 140 (37) 146 (37) 158 (36) 0.88
CV mortality or HF hospitalization 201 (43) 144 (38) 144 (36) 158 (36) 0.09
CV mortality or CV hospitalization 228 (49) 168 (45) 168 (42) 185 (42) 0.12
aValues expressed as mean +/- SD, median (25th - 75th percentile) or n (%)  
bDefined as increase in creatinine ≥0.3 mg/dl 
cDefined as ≥25% increase 
dDefined as ≥25% decrease
